The Effects of Combination of Coix Seed Extract and Cisplatin on TAM and Expression of HIF-1αin vivo in Lewis Lung Carcinoma
AbstractAbstractBackground: We investigated the combined effects of Kanglaite (KLT) and cisplatin on tumor associated macrophage (TAM) and expression of hypoxia inducible factor-1 alpha (HIF-1α) in Kunming mice with Lewis lung carcinoma. Methods: Kunming mice with Lewis lung carcinoma were randomly divided into four groups: the control (NS) group, KLT group, cisplatin (DDP) group and DDP+KLT group in Hebei People's Hospital, Hebei China from 2016 to 2017. Tumors were harvested 14 days after corresponding interventions.Results: The percentage of TAM was determined by flow cytometry and HIF-1α mRNA was detected by realtime-PCR. Tumor weight of mice in KLT group, DDP group and DDP+KLT group was significantly lower than that of NS group (P<0.01). Tumor growth inhibition rate in DDP+KLT group was higher than DDP group, (P=0.205). The spleen index was lower in the DDP group than in the NS group (P=0.005), but was significantly increased when combined with KLT (P<0.01). The percentage of TAM was higher in the DDP group than in the NS group (P=0.898); the combination with KLT significantly decreased the percentage (P=0.009<0.01). Expression of HIF-1α was lower in the KLT group and DDP+KLT group than in NS group; it was decreased more in DDP+KLT group (P<0.05). Conclusion: KLT led to pronounced antitumor activity in mice with Lewis lung carcinoma. It enhances the chemotherapeutic effect and improves immunity function when combined with cisplatin, which can be accomplished by decreasing the TAM levels and improving hypoxia status.
Liu X, Yang Q, Xi Y, , Yu K, Wang W, Zhao X, Kou X (2014). Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma. J Cancer Res Ther, 10:46-51.
Siegel R, Ma J, Zou Z, Jemal A (2014). Can-cer Statistics, 2014. CA Cancer J Clin, 64:9-29.
Qian BZ, Pollard JW (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141:39-51.
Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q (2009). Macrophages are an abundant component of myeloma microenviron-ment and protect myeloma cells from chemotheropy drug-induced apoptosis. Blood 114:3625-3628.
Shree T, Olson OC, Elie BT et al (2011). Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev, 25: 2465-2479.
Semenza GL (2014). Oxygen sensing, hy-poxia-inducible factors, and disease pa-thophysiology. Annu Rev Pathol, 9: 47-71.
Zhao T, Zhu Y, Morinibu A et al (2014). HIF-1-mediated metabolic reprogram-ming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Sci Rep, 4:3793
O'Rourke N, Edwards R (2010). Lung can-cer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol), 12:141-144.
Yang D, Tian G (2009).[Review of experi-mental study on treatment of lung cancer with traditional Chinese medicine]. Zhongguo Zhong Yao Za Zhi, 34:2405-2409
Tseng CY, Lin CH, Wu LY, Wang JS, Chung MC, Chang JF, Chao MW (2016). Poten-tial Combinational Anti-Cancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin. PLoS One, 11:e0155469.
Yang X (2013). Clinical observation of the effects of Kanglaite Injection on immune function and quality of life of patients with advanced malignant tumor. Shanxi J Tradit Chin Med, 29:20-21.
Wang JY, Guo J, Dong CS, Zheng Z, Wang Q (2012). Effects of Feiyanning Decoc-tion, a compound traditional Chinese medicine, on iNOS and COX-2 expres-sions induced by tumor necrosis factor-α in lung adenocarcinoma cell line. Zhong Xi Yi Jie He Xue Bao, 10:695-700.
Yun L, Changsheng L, and Qian D (2008). Chinese herb related molecules of can-cer-cell-apoptosis: a minireview of pro-gress between Kanglaite injection and re-lated genes. J Exp Clin Cancer Res,17:31.
Lu Y, Wu LQ, Dong Q, Li CS (2009). Ex-perimental study on the effect of Kang-Lai-Te induced apoptosis of human he-patoma carcinoma cell HepG2. Hepatobili-ary Pancreat Dis Int, 8:267-272.